Galapagos Loses Potential Ticket To America As Crohns Trial Flops
Executive Summary
The company reported the Phase III DIVERSITY trial of Jyseleca did not meet its primary endpoint in Crohn’s disease, closing another path to the US market.
You may also be interested in...
Galapagos Could Give Up On Jyseleca Over JAK Class Woes
New chief financial officer Thad Huston said that Galapagos was evaluating “various strategic options for Jyseleca,” the company’s only revenue source, given that the landscape for the JAK class in Europe “has changed significantly over the past six months.”
Galapagos Sees Global Market For Point-Of-Care CAR-T But Is Still On M&A Trail
Paul Stoffels is continuing his transformation of Galapagos into a company with CAR-T and small molecule platforms and is aiming to seal more M&A deals before the end of this year.
Paul Stoffels On Galapagos’s Turnaround And Making Its Gilead Partnership Work
After scoring a long-term multi-billion dollar deal with Gilead, Galapagos rushed into clinical trials and paid the price. Paul Stoffels talks to Scrip about returning to his Belgian roots and turning around the company he co-founded.